The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators—A pilot study

The relationship between elevated red cell distribution width and long-term outcomes among patients with atrial fibrillation

“…Finally, the medications used to treat cardiovascular disease, particularly ACEIs/ARBs, BBs and statins, are insufficient. Previous studies suggested that nebivolol and metoprolol may improve the RDW and NLR in patients with hypertension [25] and that atorvastatin may improve both RDW and MPV values in patients with hypercholesterolemia [32]. Therefore, optimal treatment may decrease the RDW, as an elevated RDW may be indicative of the presence of immature erythrocytes in the circulation.…”

Rosuvastatin and Mean Platelet Volume in Diabetes

“…Taken together, the more recent findings 28 and those from the earlier studies suggest that rosuvastatin 23,24 and atorvastatin, 25,26 but not pravastatin, 27 exert an additional beneficial action on MPV. With rosuvastatin this action is not mediated by the improved serum lipids, 28 whereas atorvastatin achieved a significant MPV reduction in patients with the strongest concomitant lipid changes.…”

“…23,24 Atorvastatin can also decrease the MPV. 25,26 Of note, this beneficial effect appears to be more pronounced in patients exhibiting the strongest lipid reduction. 25 Conversely, pravastatin treatment did not lower the MPV.…”

“…25,26 Of note, this beneficial effect appears to be more pronounced in patients exhibiting the strongest lipid reduction. 25 Conversely, pravastatin treatment did not lower the MPV. 27 More recently, the study of Akyüz et al 28 examined 178 patients with DM receiving high-dose rosuvastatin (40 mg/d) for dyslipidemia.…”

“…With rosuvastatin this action is not mediated by the improved serum lipids, 28 whereas atorvastatin achieved a significant MPV reduction in patients with the strongest concomitant lipid changes. 25 This emerging difference needs to be revisited. Given the importance of MPV as a marker of activated platelets 4 and as a predictor of vascular events, 4,6 including DM, 12,13,30 this effect of rosuvastatin and atorvastatin is encouraging.…”